Literature DB >> 9050121

Risperidone: how good is the evidence for efficacy?

J A Mattes1.   

Abstract

This article reviews the published literature evaluating the efficacy of risperidone. The literature includes three multicenter, double-blind studies that compared risperidone, haloperidol, and placebo, as well as three comparisons of risperidone with a standard neuroleptic. Efficacy of risperidone is reported, but most studies involved chronically hospitalized patients who were relatively refractory; the response to standard neuroleptics was not robust. Also, the reported superiority of risperidone on negative symptoms may be artifactual, since standard neuroleptics, because of extrapyramidal symptoms, can mimic or exacerbate negative symptoms. Finally, risperidone may have an antidepressant effect. It is as yet unclear whether risperidone is as effective as standard neuroleptics for positive schizophrenia symptoms in neuroleptic-responsive patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050121     DOI: 10.1093/schbul/23.1.155

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  4 in total

Review 1.  Antidepressant treatment in children and adolescents: bridging the gap between efficacy and effectiveness.

Authors:  J M Zito; D J Safer
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

Review 2.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

Review 3.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

4.  Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial.

Authors:  Mostafa Amr; Shaheen E Lakhan; Sarila Sanhan; Dahoud Al-Rhaddad; Moussa Hassan; Mohamed Thiabh; Tarek Shams
Journal:  Int Arch Med       Date:  2013-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.